How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Author:
Funder
Amgen (Europe)
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference127 articles.
1. Kyprolis (Carfilzomib) Summary of Product Characteristics;Amgen,2016
2. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients;Barlogie;Blood,2001
3. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy;Baz;Ann. Oncol.,2006
4. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma;Baz;Blood,2016
5. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma;Berdeja;Haematologica,2015
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs;Journal of Clinical Oncology;2023-11-10
2. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study;Leukemia & Lymphoma;2022-11-21
3. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study;The Lancet Healthy Longevity;2022-09
4. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma;Targeted Oncology;2022-06-30
5. Cancer statistics for African American/Black People 2022;CA: A Cancer Journal for Clinicians;2022-02-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3